For people diagnosed with chronic inflammatory demyelinating polyneuropathy, or CIDP, antibodies in the immune system attack healthy tissue, affecting the nerves in the arms and legs.
What is CIDP?
CIDP is a rare medical condition that can be difficult to diagnose. CIDP is most commonly experienced as weakness in the arms and legs, and may be accompanied by a prickling sensation and numbness. Symptoms can happen in waves, coming and going over time, or progress consistently.
Your healthcare team will work together to treat your CIDP. This may include neurologists, neuromuscular specialists, neurophysiologists, pharmacists, and nurses.
Your care team may choose from these available treatments:
- Intravenous immune globulin (IVIg): Adds new antibodies to the body to help block the attacking antibodies. PANZYGA is an IVIg therapy
- Corticosteroids: Help reduce inflammation and relieve symptoms
- Plasma exchange: Removes attacking antibodies from the body
- Immunosuppressants: Minimize the immune response
Causes of CIDP
In a healthy body
Neurons deliver messages between the brain and the rest of the body to perform actions like picking up a cup or taking a step. Myelin is a protective layer around a neuron—like insulation around a wire—that helps messages get to their destinations.
When someone has CIDP
The immune system, which usually recognizes foreign germs in the body and fights them off, starts to think the neurons in a person’s limbs are foreign and attacks. The immune system damages the protective myelin coating, causing the messages neurons deliver to be slowed or lost.
PANZYGA is an IVIg therapy that is FDA approved for adults with CIDP. A nurse or other member of your treatment team will give you PANZYGA by intravenous (IV) infusion, which can occur in a hospital, an infusion clinic, or at home.
In a clinical study, PANZYGA improved limb disability and impairment symptoms related to CIDP.
PANZYGA is an intravenous immunoglobulin (IVIg) therapy that was studied in patients with CIDP. Patients in the study were divided into groups, each receiving a different dose of PANZYGA. Response to treatment was dependent on the dose: the higher the dose, the more people responded.
The most common side effects of PANZYGA in the CIDP clinical study were headache, fever, skin irritation, and increased blood pressure. Allergic reactions may occur.
In the clinical study, PANZYGA infusions occurred every 3 weeks. After your starting dose, you and your doctor will work together to determine the best maintenance dose for your ongoing treatments. This dose can be adjusted as needed. PANZYGA was tested at multiple doses in the clinical study, and patients saw symptom improvement at both the 1 and 2 g/kg doses.
Learn more about CIDP by visiting this helpful website:
GBS | CIDP Foundation International
This website is neither owned nor controlled by Pfizer. Pfizer does not endorse and is not responsible for the content or services of this site.
Learn more here. When you have questions, it’s best to talk with your healthcare professional. In addition, please find some frequently asked questions and answers.
Help with managing your condition. PANZYGA offers a variety of downloadable resources with information about treatment, including guides to keep track of your therapy, and more.
All in one place. Pfizer IGuide™ can help you understand your insurance coverage and out-of-pocket costs for your prescribed PANZYGA, as well as identify financial assistance options for which you may be eligible.
Learn more here. With this program, eligible CIDP patients may get their out-of-pocket costs for PANZYGA refunded, if the treatment is discontinued by their healthcare provider for clinical reasons. Program terms and conditions apply.
Learn more. A free mobile app designed to help support the treatment experience for patients.
Sign up for additional information to help you understand more about PANZYGA and to receive free resources.